Sunil Kumar Singh

7PUBLICATIONS
11CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 10, 2024
MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFβ pathway.

Rong Ke, Navin Viswakarma, Mary Menhart

|Feb 24, 2024
The Microbiome Modulates the Immune System to Influence Cancer Therapy.

Ruchi Roy, Sunil Kumar Singh

|May 16, 2023
Molecular Insights of MAP4K4 Signaling in Inflammatory and Malignant Diseases.

Sunil Kumar Singh, Ruchi Roy, Sandeep Kumar

|Feb 22, 2023
TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer.

Rakesh Sathish Nair, Sandeep Kumar, Subhasis Das

|Jan 21, 2023
Advancements in Cancer Immunotherapies.

Ruchi Roy, Sunil Kumar Singh, Sweta Misra

|Sep 12, 2022
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles.

Sandeep Kumar, Subhasis Das, Jingjing Sun

Pageof 2